Skip to content

NTHI NTHI Convertible Preferred Stock Outstanding Shares

Convertible Preferred Stock Outstanding Shares at other companies

Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX

Other financials

Income statement

See full
Revenue$40.0K-7.0%
Operating income-$7.1M+77.9%
Net income-$8.8M+72.7%
EPS (diluted)-$0.38+78.7%

Balance sheet

See full
Cash & equivalents$138.6K-97.5%
Total debt$666.1K
Total equity-$13.2M-37.5%
Total assets$3.3M-60.6%

Cash flow

See full
Operating cash flow-$7.0M-23.7%
CapEx$125.0K
Free cash flow-$5.2M

Valuation

See full
Market cap$114.62M+51.0%
Enterprise value$115.15M+51.1%
P/S1,432.9×

Profitability

See full
Operating margin-46,870.7%
Net margin-51,613.3%
FCF margin-26,083.2%

Returns & leverage

See full
Return on equity338.1%
Debt / equity-0.1×
Current ratio0.1×-0.3×

Where this comes from

Reported directly by NTHI in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: NTHI’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about NTHI's convertible preferred stock outstanding shares.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NTHI's convertible preferred stock outstanding shares?
NTHI (NTHI) reported convertible preferred stock outstanding shares of 0 in Q1 2026.
What does convertible preferred stock outstanding shares mean?
This represents the total number of preferred shares currently held by investors that carry the right to be converted into common stock. It is a key metric for calculating fully diluted share counts and understanding potential future equity dilution. Investors monitor this to assess the impact of capital structure on common shareholder ownership.